Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of CPP-1X + sulindac versus CPP-1X or sulindac alone in familial adenomatous polyposis
NL-OMON44874Phase 3Active, not recruiting
- Sponsor
- Cancer Prevention Pharmaceuticals, Inc.
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Colonic Adenomatous Polyposis comparing CPP-1X plus sulindac, CPP-1X alone and sulindac alone (3 arms). Primary endpoint: Primary efficacy endpoint. Started Jan 2014; status: active, not recruiting.
02
Drugs
eflornithinesulindac
03
Conditions
Colonic Adenomatous Polyposis
Beyond the preview
Go deeper on NL-OMON44874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44874.